Connor, Clark & Lunn Investment Management Ltd. Veracyte, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Veracyte, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 279,331 shares of VCYT stock, worth $11.3 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
279,331
Previous 360,871
22.6%
Holding current value
$11.3 Million
Previous $12.3 Million
9.93%
% of portfolio
0.06%
Previous 0.07%
Shares
12 transactions
Others Institutions Holding VCYT
# of Institutions
336Shares Held
80.2MCall Options Held
212KPut Options Held
18.5K-
Vanguard Group Inc Valley Forge, PA8.21MShares$332 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.79MShares$315 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI6.6MShares$267 Million0.42% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.2MShares$170 Million1.46% of portfolio
-
Wellington Management Group LLP Boston, MA4.08MShares$165 Million0.03% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.89B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...